CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 91 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02283294
NCT02283294Phase 3Completed
CompareCT.gov

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

University of South Florida·interventional·Posted Nov 5, 2014·Updated Nov 30, 2021

In Brief

A Phase 3 clinical trial evaluating Apixaban and Warfarin for Transient Ischemic Attack and 2 related conditions. Completed, enrolled 91 participants across 5 sites.

Detailed Summary

The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransient Ischemic Attack, Stroke, Atrial Fibrillation
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 5, 2014
Enrollment StartApr 1, 2015
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.7 years ago

Interventions

Apixabandrug

Warfarindrug